Strepsils Junior

Quick links to important sections

Strepsils Junior

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Strepsils Junior

Quick Facts

Property Description
Active Ingredients Amylmetacresol, Dichlorobenzyl Alcohol
Form Lozenge (Oral Tablet Preparation)
Pharmacological Class Topical Antiseptic
Common Use Minor throat discomfort, Oropharyngeal infections
Origin Synthetic Compound

What Type of Medicine is Strepsils Junior?

Strepsils Junior is a commercially branded oral medicinal preparation that is primarily classified as a Topical Antiseptic, specifically formulated for local use in the oropharyngeal region. As an Over-the-Counter (OTC) medication, it is readily available for symptomatic relief. The preparation is presented as a lozenge, a solid oral tablet preparation for oromucosal administration, which is clinically recognized for providing a sustained surface contact time of the active ingredients with the throat mucosa. Its distinct positioning is focused on the pediatric patient group, specifically children aged six years and over.

Composition and Origin: A Synthetic Fixed-Dose Combination

The active composition utilizes a fixed-dose combination of two distinct synthetic compounds: Amylmetacresol (AMC) and Dichlorobenzyl Alcohol (DBA). Both agents are chemically synthesized and delivered through excipients in the lozenge base to facilitate controlled dissolution. This specific pairing facilitates a local antibacterial action of these agents against common throat pathogens. The formulation’s reliance on these established synthetic agents distinguishes it from preparations that rely solely on herbal extracts or simple demulcents.

General Purpose: Localized Action for Minor Throat Discomfort

The general purpose of the lozenge is to provide localized relief and address minor throat discomfort associated with common irritations. Its localized antibacterial action against surface microorganisms offers a means of hygiene and symptomatic care. This effect is non-systemic, meaning the action is confined to the throat and mouth, helping to manage the microbial load contributing to irritation for the intended patient group.

Regulatory References

  1. Clinical Trials Register, EU CTR 2005-001045-31

What side effects are possible with Strepsils Junior?

Possible Side Effects and Safety Information

The official safety information for lozenges containing Amylmetacresol and Dichlorobenzyl Alcohol organizes potential effects according to established regulatory standards. All documented adverse reactions are formally classified with a "Not known" frequency, meaning their incidence cannot be reliably estimated from available data collected during use.

Adverse Reaction Classifications

The possible adverse reactions, as documented in regulatory sources, are grouped into three primary System-Organ Classes:

  • Immune System Disorders
  • Gastrointestinal Disorders
  • Skin and Subcutaneous Tissue Disorders

Specific reactions within these categories may include hypersensitivity, abdominal pain, nausea, and various forms of oral discomfort (such as throat irritation or oral paraesthesia).

Serious Adverse Reactions and Safety Constraints

Potential serious hypersensitivity reactions are documented and may manifest as severe symptoms, including bronchospasm, angioedema (swelling beneath the skin), and hypotension with syncope (low blood pressure leading to fainting). Use is contraindicated in individuals with a known hypersensitivity to the active ingredients or any excipients.

Specific population restrictions are noted in the official profile. The product is not suitable for children under six years old. Furthermore, avoidance is advised during pregnancy and lactation, and the lozenge is contraindicated in individuals with rare hereditary problems, such as fructose intolerance or glucose-galactose malabsorption. A high-level safety pattern also cautions that additional adverse effects may occur under prolonged or long-term treatment.

Overdose and Emergency Response

The regulatory documentation for lozenges containing Amylmetacresol and Dichlorobenzyl Alcohol specifies a profile of minimal expected severity in the event of overdosage. Official government health authorities assess the potential risk as low due to the local, antiseptic nature of the active ingredients, classifying the outcome as highly unlikely to result in serious effects.

Documented Overdose Manifestations

The specific findings detailed in the regulatory Summary of Product Characteristics (SmPC) detail only one primary clinical sign associated with consuming quantities beyond the maximum recommended dose.

Feature Official Regulatory Finding
Documented Manifestation Gastrointestinal discomfort is the sole clinical sign officially noted in the event of overdosage.
Antidote Availability No specific antidote is documented in the regulatory information for this fixed-dose combination.

Required Emergency Actions

The official guidance regarding management and when to seek help is limited to supportive measures. No explicit command to contact emergency services or seek immediate medical attention is included in the reviewed overdose sections of regulatory documents. The official procedural instruction is defined as follows: Treatment should be symptomatic.

This regulatory instruction confirms that management is focused on relieving the single documented clinical presentation (discomfort) rather than counteracting systemic or severe toxic effects, reflecting the low potential for serious outcomes as assessed by regulatory bodies.

Therapeutic Uses of Strepsils Junior

What Strepsils Junior Treats: Main Uses and Benefits

The primary therapeutic role of Strepsils Junior supports localized, symptomatic relief for the symptoms related to physical discomfort associated with common throat and mouth irritations in children aged six years and over. The product is indicated for the symptomatic relief of mouth and throat infections. It is commonly used across conditions presenting with acute episodes and is used for managing symptom clusters that may become intense or disruptive.


The lozenge is relevant for easing the distressing manifestations of a sore throat, including localized pain, soreness, scratchiness, and associated difficulty in swallowing. This application supports symptomatic relief in conditions such as minor mouth infections and pharyngitis (throat inflammation). It is commonly used when short-term symptomatic assistance is needed, helping to address symptom clusters that interfere with daily comfort. This focused relief contributes to easing the overall symptom load during periods of heightened symptoms.

“The primary benefit is targeted support for symptomatic relief, assisting with maintaining functional stability during symptomatic phases.”

Quick Fact Relief for Symptom
Primary Indication Minor Oropharyngeal Infections
Symptomatic Relief Pain, Soreness, and Difficulty Swallowing
Target Group Children aged six years and older

Regulatory References

  1. NAFDAC Summary of Product Characteristics

Eligibility and Restrictions for Use

Strepsils Junior (Amylmetacresol / 2,4-Dichlorobenzyl Alcohol) is officially indicated for use by children over 6 years old, as well as adults and the elderly. The regulatory profile establishes clear constraints and contraindications based on age, allergy status, and specific medical conditions.

Populations Who Must Not Use the Medicine (Contraindicated)

  • Children under 6 years old are strictly contraindicated from using the product. This exclusion is often based on the risk of choking on the lozenge format.
  • Individuals with a known hypersensitivity (allergy) to the active substances (Amylmetacresol or 2,4-Dichlorobenzyl Alcohol) or any other component (excipients) in the formulation.
  • Patients diagnosed with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency. This is due to the presence of sugars like glucose and sucrose in certain formulations.

Considerations for Use

  • Pregnancy and Lactation: There are limited data on the use of the active substances during pregnancy and breast-feeding. As a precautionary measure, the use of this medicine is generally not recommended unless deemed necessary after seeking medical advice, as a risk to the newborn cannot be excluded during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official regulatory information regarding potential interactions for Strepsils Junior, which contains the active ingredients Amylmetacresol (AMC) and Dichlorobenzyl Alcohol (DBA).

Regulatory authorities, including national medicines agencies, have assessed the interaction profile of this lozenge formulation. The consensus is that due to the topical and non-systemic nature of the medication, the risk of clinically relevant drug-drug interactions is minimal.


Official Documented Interaction Profile

Interaction Type Regulatory Statement
Drug-Drug Interactions No clinically significant interactions are known or formally documented with other medicinal products.
Contraindicated Combinations No medicinal products are explicitly classified as contraindicated due to an interaction risk with Strepsils Junior.
Food, Alcohol, or Supplements No interactions with food, alcohol, supplements, or herbal products are explicitly documented in the official regulatory labels.
Timing Requirements No mandatory timing separation for administration with other medicines is required or listed.

The official labeling confirms that the active components demonstrate minimal systemic exposure and therefore do not require specific restrictions or dosage adjustments when co-administered with other treatments. This structure reflects the regulatory finding that Amylmetacresol and Dichlorobenzyl Alcohol, when used as a lozenge, do not significantly alter the body's processing of other medications.

Mechanism of Action

The primary active agents in Strepsils Junior are typically Amylmetacresol (AMC) and 2,4-Dichlorobenzyl Alcohol (DCBA), which exhibit dual pharmacodynamic actions: antimicrobial activity and local channel modulation.

How Strepsils Junior Works

The mechanism is initiated by the localized deposition of the active agents onto the oropharyngeal mucosa. Amylmetacresol and 2,4-Dichlorobenzyl Alcohol are phenol-based antiseptics that target the cell membranes of microorganisms. This interaction disrupts the structural integrity of the bacterial and fungal cell walls and the lipid envelope of enveloped viruses. This physical perturbation increases the permeability of the microbial membrane, leading to the leakage of intracellular contents and subsequent microbial lysis. DCBA is understood to augment the action of AMC, resulting in a synergistic anti-microbial effect.

Concurrently, these compounds exhibit activity as antagonists at voltage-gated neuronal sodium channels in the local tissue. This receptor interaction decreases the depolarization-induced ion flow across the neuronal membrane, which modulates the initiation and conduction of local nerve impulses. This dual cascade ensures both an antiseptic effect at the mucosal surface and a local inhibitory action on sensory nerve signaling.

Dosage and Administration Information

Strepsils Junior is an oral tablet preparation designed exclusively for oromucosal administration, which means the lozenge must be slowly dissolved in the mouth to achieve its localized action. It is essential that the lozenge is not swallowed whole or chewed, as the product's intended use relies on sustained surface contact with the oropharyngeal mucosa.

The dosing regimen requires the administration of one lozenge per dose. For both adults and children aged six years and older, the dose may be repeated with an interval of 2 to 3 hours between administrations. A strict limit is placed on the total daily intake, which must not exceed a maximum of 12 lozenges within any 24-hour period. The core principle is to utilize the lowest necessary dose for the shortest duration required for symptom relief.

Use is explicitly restricted to children aged six years and over; the lozenge is not suitable for administration to children under six. For older adults, the labeling indicates that no adjustment to the standard dosage is necessary. The product is intended for short-term use only, and the guidance for use specifies that self-treatment should not exceed a maximum of 3 days. If symptoms do not improve, persist, or worsen after this 3-day period, consultation with a healthcare professional is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Strepsils Junior

This section outlines the structure of the clinical research conducted for the active ingredients in Strepsils Junior (Amylmetacresol and Dichlorobenzyl Alcohol), focusing on what has been studied and what the research evidence describes, according to official scientific and regulatory sources.


Evidence for Use in Acute Sore Throat Symptoms

Research on the active ingredients has primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews to explore symptom patterns related to minor throat and mouth discomfort. These studies examined outcomes typically recorded as patient-reported outcomes, including subjective scores for throat soreness severity and reports on difficulty in swallowing.

Research has explored the measurement of sore throat pain scales in studies comparing the study lozenge to a non-medicated, placebo lozenge. Studies report patterns observed, with results documented during the immediate hours following administration. Evidence remains limited and heterogeneous, with reported observations generally restricted to these immediate, short-term periods.


Scope of Study Populations and Extrapolation

What remains uncertain is the full scope of the observed patterns in the research. Long-term effects are not fully established, and there is limited information available that describes sustained relief or maintenance outcomes for fluctuating symptoms. Furthermore, dedicated research on the intended outcome is primarily derived from studies in adult populations, and data for children aged six and older is limited.

Specific research has also examined the acceptability and palatability of the 'Junior' formulation for children. These studies monitored scores related to the lozenge's taste profile but provide no data regarding the lozenge's ability to help with sore throat pain. The study results reflect the specific conditions under which they were conducted (healthy subjects) and are limited to assessing acceptance, not therapeutic effect.

Key Studies & References

  1. NAFDAC Summary of Product Characteristics (SMPC) for Strepsils Junior (Amylmetacresol/Dichlorobenzyl Alcohol)
  2. NICE Evidence Summary ES27: Sore throat - antimicrobial lozenges (Key findings and evidence)

Frequently Asked Questions (FAQ)

Common questions about Strepsils Junior (FAQ)


Q: What is the difference between Strepsils Junior and regular Strepsils?

A: The Junior lozenges typically contain the same core active ingredients, Amylmetacresol and 2,4-Dichlorobenzyl Alcohol, as the standard adult version. However, differences may exist in the inactive ingredients (excipients) used for flavoring or coloring. Other Strepsils products may be formulated with entirely different active components, such as Flurbiprofen or Hexylresorcinol.


Q: Does Strepsils Junior contain antibiotics?

A: No, Strepsils Junior is not classified as an antibiotic. The active ingredients are described as topical antiseptics. These substances have antimicrobial properties that work locally on the surface of the mouth and throat to help manage the microbial load.


Q: Can Strepsils Junior be taken on an empty stomach?

A: Official regulatory documents do not specify any mandatory requirements or restrictions regarding the consumption of food or drink before or after taking the lozenge. It is designed to dissolve in the mouth for localized action.


Q: Are there any common food or drink interactions with Strepsils Junior?

A: According to official regulatory documents, no interactions with food, alcohol, supplements, or herbal products are explicitly documented for this product. This structure is consistent with the regulatory finding of low systemic absorption.


Q: Are there different flavors of Strepsils Junior?

A: Yes, lozenges are formulated with specific inactive ingredients (excipients) to provide a characteristic flavor, which may vary by region or product line. This information is detailed in the official composition section.


Q: Does Strepsils Junior make you drowsy?

A: Official product labeling states that no adverse effects on the ability to drive or use machines are known. This indicates the product is not expected to cause drowsiness.


Q: Is there any sugar in Strepsils Junior?

A: The presence of sugar depends on the specific formulation. Some variants are documented as 'Sugar-Free' and use substitutes like Isomalt. Other variants may contain ingredients such as liquid glucose or sucrose, which are listed in the official excipient section.


Q: What happens if you use Strepsils Junior after the expiration date?

A: The expiration date specifies the period during which the product is confirmed by manufacturers and regulators to retain its intended strength, quality, and purity when stored correctly.


Q: What is the role of the active ingredients in Strepsils Junior?

A: The two active agents, Amylmetacresol and 2,4-Dichlorobenzyl Alcohol, are described as working together to provide antiseptic action and a local inhibitory effect on sensory nerve signaling in the throat tissue.


Q: Does Strepsils Junior interact with asthma medication?

A: Due to the medicine's topical and non-systemic nature, official documentation states that no clinically significant interactions are known with other medicinal products, including typical respiratory or asthma medication.


Q: Why do some people find Strepsils Junior helpful for a scratchy throat?

A: The lozenge is indicated for localized relief of minor throat discomfort. The product's mechanisms include a local inhibitory action on sensory nerve signaling, which is described as modulating local nerve impulses in the throat tissue.


Q: Is Strepsils Junior similar to lozenges that contain benzocaine?

A: The active ingredients, Amylmetacresol and 2,4-Dichlorobenzyl Alcohol, are described in official documents as agents that reversibly block depolarization-induced ion channels. This function is similar to the mechanism used by some local anesthetic agents.


Q: Does the junior version have lower doses than the adult version?

A: The quantity of active ingredients in the Junior formulation is typically the same as the standard adult lozenge, which contains 0.6 mg of Amylmetacresol and 1.2 mg of 2,4-Dichlorobenzyl Alcohol. The official difference is in the recommended frequency and total daily intake for children.


Q: Are there any known interactions with herbal supplements?

A: Official regulatory documents do not contain specific information regarding interactions with herbal products or supplements. The low systemic exposure of the lozenge is considered to minimize the potential for drug interactions.


Q: Are there considerations for a child with a known heart condition when using Strepsils Junior?

A: Due to the topical administration, the product's active ingredients demonstrate minimal systemic exposure, meaning they are not widely distributed in the body. Official product information does not list major cardiovascular interactions.


Q: Does Strepsils Junior cause bad breath?

A: Bad breath (halitosis) is not listed as a documented adverse reaction in the official safety profile for the lozenge.


Q: Can this medicine be used alongside saline nasal sprays?

A: No known interactions are documented with other medicinal products. This includes topically administered products like saline nasal sprays, which act locally in the nasal cavity.


Q: Does Strepsils Junior contain any alcohol?

A: The official list of excipients (inactive ingredients) in the lozenge formulation does not include ethanol or other typical pharmaceutical alcohols.


Q: Is Strepsils Junior suitable for someone with lactose intolerance?

A: Official documents list warnings for ingredients related to fructose and glucose-galactose malabsorption. However, lactose is not listed in the excipient section of the standard formulation.


Q: Why is the dosage limited for children?

A: The limit on the total daily intake reflects the core regulatory principle for over-the-counter topical products: utilize the lowest necessary dose for the shortest duration. This establishes a clear constraint for use in children.


Q: Are there special considerations for children with kidney issues when using Strepsils Junior?

A: Because the lozenge demonstrates minimal systemic exposure, official labeling does not indicate a need for dosage adjustment for children who may have kidney issues.


Q: How long does the effect of Strepsils Junior usually last?

A: Official administration instructions permit the lozenge to be repeated every 2 to 3 hours as needed. This time frame describes the typical interval permitted between doses.


Q: What should I do if my child accidentally takes too many?

A: Official product information states that overdosage is considered highly unlikely, but if it occurs, it may result in gastrointestinal discomfort. Regulatory advice indicates that any treatment administered should be supportive and symptomatic.


Q: Is it okay to take Strepsils Junior with paracetamol (acetaminophen)?

A: Regulatory documents state that no clinically significant interactions are known or formally documented with other medicinal products, including paracetamol (acetaminophen), due to the lozenge's localized action.


Q: Can Strepsils Junior be taken with common cold and flu remedies?

A: No specific interactions are documented with other medicinal products. The lozenge’s topical and non-systemic nature means the risk of interactions with common cold and flu remedies is considered minimal.


Q: Is there a maximum number of days a child should use Strepsils Junior?

A: The regulatory guidance advises that self-treatment with the lozenge should not exceed a maximum of 3 days. If symptoms persist or worsen after this period, the protocol indicates the need for consultation with a healthcare professional.


Q: What should I avoid doing right after taking Strepsils Junior?

A: The lozenge is for oromucosal administration and must be dissolved slowly in the mouth to ensure sustained local contact with the throat and mouth tissue. To facilitate this sustained contact, the lozenge is intended to dissolve slowly in the mouth.


Q: Can Strepsils Junior be used for a cough?

A: The product is officially indicated for the symptomatic relief of infections and discomfort in the mouth and throat, commonly associated with sore throats. Specific Strepsils variants containing other ingredients are typically formulated for cough relief.


Q: Has Strepsils Junior been tested in clinical studies?

A: Clinical studies have examined the active ingredients in the lozenge for effects on throat soreness. Furthermore, research has been conducted specifically on the 'Junior' formulation to assess its acceptability and palatability for children.

How should Strepsils Junior be stored and disposed of?

How to Store and Dispose of Strepsils Junior

Strepsils Junior lozenges must be stored correctly to maintain stability and effectiveness. The product should be kept in its original packaging and stored in the outer carton to provide necessary protection from light and moisture. The maximum labeled storage temperature is 25 C. The unopened product typically has a shelf-life of 36 months, and for similar forms, stability upon opening may be restricted to three months. It is officially mandated that the product must be stored out of the reach of children.

Disposal instructions state that appropriate containment must be used to avoid environmental contamination, and disposal of large quantities should occur via a licensed waste disposal contractor. Do not dispose of unused medication in household waste or flush down the toilet unless explicitly instructed to do so by a pharmacist or local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Strepsils Junior found in:

A-Z Index: